200 related articles for article (PubMed ID: 16134271)
1. AIDS researchers, activists to face off over drug studies.
Chase M
Wall St J (East Ed); 2005 May; ():B7. PubMed ID: 16134271
[No Abstract] [Full Text] [Related]
2. AIDS vaccines: what chance of a fair trial?
Brown P
New Sci; 1991 Apr; 130(1766):33-7. PubMed ID: 11656066
[No Abstract] [Full Text] [Related]
3. Access to AIDS treatment in developing countries: a global issue of equity and human rights.
Thomas J
AIDS Anal Asia; 1998 Mar; 4(2):2-4. PubMed ID: 11657713
[No Abstract] [Full Text] [Related]
4. Human experimentation in developing countries: improving international practices by identifying vulnerable populations and allocating fair benefits.
Farrell K
J Health Care Law Policy; 2006; 9(1):136-61. PubMed ID: 17165228
[No Abstract] [Full Text] [Related]
5. African AIDS: whose research rules?
Palca J
Science; 1990 Oct; 250(4973):199, 201. PubMed ID: 11653984
[No Abstract] [Full Text] [Related]
6. Ethics and AIDS drugs.
Dowell W
Time; 1999 Jul; 154(2):49. PubMed ID: 10538646
[No Abstract] [Full Text] [Related]
7. Ethics and AIDS drugs: some countries want to suspend patent and trade laws to get lower-cost medications to the poor.
Dowell W
Time; 1999 Jul; 152(4):49. PubMed ID: 11657653
[No Abstract] [Full Text] [Related]
8. HIV preventive vaccine research and access to anti-retrovirals.
Landman WA; Schuklenk U
Dev World Bioeth; 2001 Nov; 1(2):iii-v. PubMed ID: 12870516
[No Abstract] [Full Text] [Related]
9. Controversial AIDS vaccine to be tested in China.
Brown P
New Sci; 1993 May; 138(1875):7. PubMed ID: 11656245
[No Abstract] [Full Text] [Related]
10. No money, no meds.
Mabry M
Newsweek; 1999 Jul; 134(2):32-3. PubMed ID: 10538648
[No Abstract] [Full Text] [Related]
11. Ethical considerations in AIDS vaccine trials.
Mehendale S
Issues Med Ethics; 2000; 8(1):13-5. PubMed ID: 16323332
[No Abstract] [Full Text] [Related]
12. Trials and errors: with drug companies now testing new medicines in all parts of the globe, are ethical standards being compromised?
Concar D
New Sci; 2003 Jun; 178(2400):28. PubMed ID: 14686411
[No Abstract] [Full Text] [Related]
13. In that case: your company has invested heavily in developing an AIDS vaccine and wishes to embark on clinical trials. Commentary.
Evans D
N Z Bioeth J; 2001 Oct; 2(3):37-8. PubMed ID: 15587008
[No Abstract] [Full Text] [Related]
14. Bush declines to support drug companies' line on AIDS profits.
Dickson D
Nature; 2001 Mar; 410(6824):3. PubMed ID: 11241998
[No Abstract] [Full Text] [Related]
15. Fitting a square peg into a round hole?: imposing informed consent and post-trial obligations on United States sponsored clinical trials in developing countries.
Chang E
South Calif Interdiscip Law J; 2002; 11(2):339-60. PubMed ID: 15732187
[No Abstract] [Full Text] [Related]
16. Activists now urge caution on approval of new AIDS drug.
MacIlwain C
Nature; 1993 Sep; 365(6445):378. PubMed ID: 8413575
[No Abstract] [Full Text] [Related]
17. Twenty-five years of AIDS.
Cameron DW
CMAJ; 2006 Aug; 175(3):225, 227. PubMed ID: 16880433
[No Abstract] [Full Text] [Related]
18. Harmonizing regulations for biomedical research: a critical analysis of the US and Venezuelan systems.
Di Tillio-Gonzalez D; Fischbach RL
Dev World Bioeth; 2008 Dec; 8(3):167-77. PubMed ID: 17488491
[TBL] [Abstract][Full Text] [Related]
19. Perspectives. Researchers protest congressional "meddling".
Kent C
Faulkner Grays Med Health; 1992 Nov; 46(45):suppl 4 p.. PubMed ID: 10121800
[No Abstract] [Full Text] [Related]
20. A challenging case: how should an IRB rule when a protocol calls for using an extremely vulnerable population: the dying?
Agich G; Smith D; Levine R
Prot Hum Subj; 2005; (12):5-6. PubMed ID: 16317856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
